Reata Pharmaceuticals Inc - Ordinary Shares - Class A
NASDAQ:RETA
| Market Cap (Intraday) | 3.97B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $109.24 |
| 50-Day MA | $114.29 |
| 200-Day MA | $116.38 |
Reata Pharmaceuticals Inc - Ordinary Shares - Class A Stock, NASDAQ:RETA
5320 Legacy Drive, Suite 150, Plano, Texas 75024
United States of America
Phone: +1.972.865.2219
Number of Employees: 273
Description
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.